Singapore, July 22 -- Chengdu Kanghua Biological Products Co. has announced that Shanghai Healthcare M&A Fund intends to acquire the company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu.

The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialised products with best-in-class R&D capabilities.

As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine - stands as China's first domes...